Recruiting

SGB

Sponsor:

Stanford University

Code:

NCT06953661

Conditions

Postural Tachycardia Syndrome

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Stellate ganglion block

Sham injection of saline

Ropivacaine

Normal saline

Study Details

Brief summary:

This single-center study aims to evaluate both immediate and long-term outcomes of stellate ganglion block (SGB) in a cohort of rigorously phenotyped patients with Postural Tachycardia Syndrome (POTS). By assessing the effects of SGB, this study seeks to determine its viability as an intervention for symptom control in POTS.

Conditions

Postural Tachycardia Syndrome

Study ID

NCT06953661

Start date

Oct 16, 2025

Status verified date

Oct, 2026

Completion date

May, 2027

Anticipated

Primary completion date

May, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adult patients (>18 years of age) diagnosed with POTS
  • Ability to provide informed consent
  • Ability to comply with 3 follow up visits
  • English speaking and capable of signing informed consent and complying with protocol requirements

Exclusion Criteria:

  • Allergy to local anesthetics
  • Severe coagulopathy
  • History of or currently being treated for clinically significant ongoing cardiac arrhythmia, heart failure, myocarditis, pulmonary embolism requiring anticoagulation, pulmonary fibrosis or other pulmonary diagnosis that in the investigator's opinion may contribute to symptoms of POTS
  • Inability to maintain a stable medication regiment for the duration of the study

Study Design

Enrollment

20 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Intervention Group (stellate ganglion block)

Patients will receive an ultrasound guided stellate ganglion block (SGB) with 10 ml of 0.5% ropivacaine.

sham comparator: Control Group (sham injection with saline)

Patients will receive a subcutaneous sham injection with saline. Ultrasound imaging will be used to simulate the guidance process as in the active procedure, maintaining consistency in the procedural experience.

Interventions

Stellate ganglion block

Patients will receive a SGB

Sham injection of saline

Patients will receive a subcutaneous sham injection of saline

Ropivacaine

The SGB group will receive ropivacaine 0.5% 10ml

Normal saline

The control group will receive normal saline in the sham injection.

Primary outcome measure

  • COMPASS 31 total score [ Time Frame: Baseline (day -21 to -1 before intervention), first follow-up (day 1 to 21 after the intervention) and second follow-up (day 74 to 94 after the intervention) ]

Central Contacts and Locations

Central contacts

Anna Maria Bombardieri, MD, PhD

3143269107abomba@stanford.edu

Ksenia Kasimova, MD

6507889458kasimova@stanford.edu

Locations

Stanford University School of Medicine

Recruiting

Stanford, California, United States, 94304

Contacts

Anna Maria Bombardieri, MD, PhD

314-326-9107abomba@stanford.edu

Stanford University

Recruiting

Stanford, California, United States, 94305

Contacts

Anna Maria Bombardieri, MD

abomba@stanford.edu

More Information

Sponsor

Stanford University

Last update posted

Oct 28, 2026

Last verified

Oct, 2026

Keywords

  • stellate ganglion block
  • regional anesthesia
  • nerve block

Trial information was received from ClinicalTrials.gov and was last updated on 2026-10-29. This information was provided to ClinicalTrials.gov by Stanford University on 2026-10-28. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.